Trial · NCT03287310
Results by group3,509
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 3,509
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Adverse Events (AEs) and Serious AEs (SAE) | Placebo | Any AE | 11 | Participants | |
| Number of Participants With Adverse Events (AEs) and Serious AEs (SAE) | GSK3511294 2mg | Any AE | 2 | Participants | |
| Number of Participants With Adverse Events (AEs) and Serious AEs (SAE) | GSK3511294 10mg | Any AE | 6 | Participants | |
| Number of Participants With Adverse Events (AEs) and Serious AEs (SAE) | GSK3511294 30mg | Any AE | 8 | Participants | |
| Number of Participants With Adverse Events (AEs) and Serious AEs (SAE) | GSK3511294 100mg | Any AE | 9 | Participants | |
| Number of Participants With Adverse Events (AEs) and Serious AEs (SAE) | GSK3511294 300mg | Any AE | 4 | Participants | |
| Number of Participants With Adverse Events (AEs) and Serious AEs (SAE) | Placebo | Any SAE | 0 | Participants | |
| Number of Participants With Adverse Events (AEs) and Serious AEs (SAE) | GSK3511294 2mg | Any SAE | 0 | Participants | |
| Number of Participants With Adverse Events (AEs) and Serious AEs (SAE) | GSK3511294 10mg | Any SAE | 0 | Participants | |
| Number of Participants With Adverse Events (AEs) and Serious AEs (SAE) | GSK3511294 30mg | Any SAE | 0 | Participants | |
| Number of Participants With Adverse Events (AEs) and Serious AEs (SAE) | GSK3511294 100mg | Any SAE | 0 | Participants | |
| Number of Participants With Adverse Events (AEs) and Serious AEs (SAE) | GSK3511294 300mg | Any SAE | 0 | Participants | |
| Number of Participants With Adverse Events of Special Interest (AESI) | Placebo | Hypersensitivity | 0 | Participants | |
| Number of Participants With Adverse Events of Special Interest (AESI) | GSK3511294 2mg | Hypersensitivity | 0 | Participants | |
| Number of Participants With Adverse Events of Special Interest (AESI) | GSK3511294 10mg | Hypersensitivity | 0 | Participants | |
| Number of Participants With Adverse Events of Special Interest (AESI) | GSK3511294 30mg | Hypersensitivity | 1 | Participants | |
| Number of Participants With Adverse Events of Special Interest (AESI) | GSK3511294 100mg | Hypersensitivity | 0 | Participants | |
| Number of Participants With Adverse Events of Special Interest (AESI) | GSK3511294 300mg | Hypersensitivity | 0 | Participants | |
| Number of Participants With Adverse Events of Special Interest (AESI) | Placebo | Injection Site Reaction: hematoma | 1 | Participants | |
| Number of Participants With Adverse Events of Special Interest (AESI) | GSK3511294 2mg | Injection Site Reaction: hematoma | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03287310/results